Although it's ranked No. 4, this asthma inhaler is in the No. 1 spot when it comes to annual growth. GlaxoSmithKline must have been breathless with its 19 percent annual growth rate. Sales for Seretide/Advair were just slightly lower than those for Nexium, coming in at $5.6 billion.